Browse the evidence

Relying solely on Fasting Plasma Glucose (FPG) for diagnosis misses a significant number of diabetes cases in Korean populations; OGTT or HbA1c is required for accurate diagnosis.

If you are Asian or have a lower body weight, a normal fasting blood sugar might not mean you are safe. You may have high blood sugar after eating. Ask your doctor about an OGTT or HbA1c test if you have risk factors.

HbA1c is a valid diagnostic criterion for diabetes (≥6.5%) in Korea, but it should not be used alone due to lower detection rates compared to combined FPG and OGTT.

HbA1c is a convenient test that doesn't require fasting, but it might miss diabetes if used alone. For the most accurate diagnosis, especially if you have conditions like anemia or kidney disease, combine it with fasting glucose or an OGTT.

Triple agonists targeting GLP-1, GIP, and Glucagon receptors improve energy expenditure and restore body weight in diet-induced obesity models more effectively than dual or mono-agonists.

Triple hormone agonists (GLP-1/GIP/Glucagon) are in development and show promise in animal studies for boosting energy expenditure and weight loss beyond what dual agonists achieve. They are not yet standard clinical care.

GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.

The addition of GIP receptor activation in dual agonists may help improve insulin sensitivity through metabolic pathways in fat tissue, independent of just losing weight.

Semaglutide therapy in older adults with type 2 diabetes accelerates muscle mass loss and functional decline, with higher doses and lower baseline muscle mass predicting greater loss.

If you are taking Semaglutide and are over 65 with diabetes, monitor your muscle strength. The medication can cause muscle loss, especially at higher doses. To counter this, focus on resistance training and adequate protein intake, and discuss dose adjustments with your doctor if you notice weakness.

Social media platforms (Instagram, TikTok) misrepresent semaglutide by promoting off-label weight loss use while omitting common adverse effects like gastrointestinal disorders, leading to unreflected medication use and supply shortages for indicated patients.

If you are considering semaglutide for weight loss, understand that it is a prescription medication with significant side effects, primarily gastrointestinal issues. Social media often omits these risks. Consult a healthcare provider to ensure it is appropriate for you and to avoid contributing to shortages for diabetic patients.

Tirzepatide treatment in high-fat diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) mice significantly reduces hepatic lipid accumulation and liver damage by downregulating fatty acid uptake proteins (Cd36, Fabp2/4) and upregulating cholesterol efflux regulators (Hnf4a, Abcg5, Abcg8).

For individuals with fatty liver disease, tirzepatide (a dual GIP/GLP-1 agonist) has been shown in preclinical models to reduce liver fat and inflammation. It works by decreasing fatty acid uptake and increasing cholesterol excretion. While promising, these results are from mice, and human clinical data is needed to confirm efficacy and safety for liver health specifically.

Semaglutide use is associated with a significantly higher reporting odds ratio for vision impairment and retinopathy compared to other GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, metformin, phentermine, and orlistat.

If you are taking semaglutide, be aware that there is a statistical signal for increased vision impairment reports in post-market data compared to other diabetes or weight loss drugs. This does not mean everyone will experience this, but it warrants vigilance. Ensure you have regular ophthalmological check-ups, especially if you have pre-existing diabetic retinopathy or rapid glycemic changes, and report any visual disturbances to your provider immediately.

Intravenous amino acid infusion improves muscle protein synthesis and reduces perioperative blood loss in total joint arthroplasty patients.

If your surgical team recommends intravenous amino acids during your joint replacement, it may help preserve muscle protein and reduce blood loss. This is a specific medical intervention that complements your surgery, not a substitute for post-operative nutrition.

DPP-4 inhibitors, specifically sitagliptin, are significantly associated with an increased risk of biliary disorders, including gallbladder-related diseases and biliary malignant tumors.

If you are taking a DPP-4 inhibitor (like sitagliptin), be aware of symptoms like right-sided abdominal pain, nausea, or fever, which could indicate gallbladder issues. Discuss these risks with your doctor, especially if you have been on the medication for a long time.

Specific GLP-1 receptor agonists, semaglutide and liraglutide, are significantly associated with an increased risk of biliary disorders, including gallbladder-related diseases and biliary malignant tumors.

If you are taking Semaglutide or Liraglutide, watch for signs of gallbladder problems, such as pain in the upper right abdomen, nausea, or fever. These drugs can slow down your gallbladder, so report any such symptoms to your doctor promptly.

Genetic variants in GLP1R that increase weight loss efficacy are also associated with an increased risk of nausea and vomiting, suggesting a link between efficacy and side effects.

Research suggests that the same genetic factors that help you lose more weight with GLP-1 medications may also make you more prone to nausea and vomiting. This doesn't mean you must suffer, but it highlights why side effects vary so much between individuals. If you are struggling with severe side effects, it might be worth discussing with your doctor whether a different medication or dose adjustment could help, as your genetics might be driving both your response and your side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily) cause modest bone mineral density (BMD) reduction and increase bone turnover markers (favoring resorption) in people living with obesity, mirroring the effects of calorie restriction.

If you are taking GLP-1 agonists like Wegovy or Saxenda for weight loss, expect a small decrease in bone density (around 2-3%) over a year, similar to losing weight through diet alone. This is not unique to the drug but to the weight loss itself. To protect your bones, prioritize resistance training and ensure you are getting enough calcium and Vitamin D. The benefit of weight loss generally outweighs this modest skeletal risk, but monitoring is advised.

GLP-1 receptor agonists provide neuroprotective benefits, including potential improvement in cognitive function and reduction in neurodegenerative disease progression (Alzheimer's and Parkinson's).

GLP-1 RAs are being studied for their potential to protect the brain in Alzheimer's and Parkinson's disease. They may reduce inflammation and oxidative stress in the brain. While not yet a standard treatment for these conditions, the biological plausibility is strong, and patients with these diseases should discuss the potential benefits with their neurologist.

GIP receptor antagonism promotes weight loss and protects against diet-induced obesity, potentially by enhancing leptin sensitivity in the hypothalamus and reducing lipid storage in adipose tissue.

Research indicates that blocking the GIP receptor (antagonism) can also lead to weight loss, possibly by improving how your body responds to leptin and reducing fat storage. This is an emerging area of treatment, with some drugs in clinical trials combining GIP antagonism with GLP-1 agonism for enhanced effects.

Resistance training does not significantly improve appendicular skeletal muscle mass (ASM) or appendicular skeletal muscle mass index (ASMI) in older adults with sarcopenia.

Do not expect resistance training to significantly increase your muscle mass or muscle mass index if you have sarcopenia. The benefits you feel (strength, balance) are likely due to your nervous system working better, not your muscles getting bigger. This is still a positive outcome for function, even if the scale or tape measure doesn't change much.

Spirulina supplementation does not significantly reduce waist circumference in the general adult population, though it may benefit obese individuals over 40.

Do not expect Spirulina to significantly reduce waist circumference for the general population. However, if you are obese and over 40, taking ≥2g/day may help. Focus on its proven benefits for overall weight and body fat reduction instead.

Public health strategies targeting the obesogenic environment (e.g., SSB taxes, zoning, produce prescriptions) are necessary to support individual weight management efforts, as individual lifestyle advice is undermined by environmental factors.

Individual willpower is not enough in an environment designed to promote obesity. Support public health policies like sugar taxes, zoning for healthy food access, and produce prescription programs. These environmental changes make healthy choices easier and more affordable.

Long-term intermittent fasting (IF) protocols, particularly time-restricted eating (TRE) with short windows (e.g., 8 hours), are associated with increased cardiovascular disease (CVD) mortality and adverse cardiac structural changes, primarily mediated by lean mass loss, circadian misalignment, and reward-based poor dietary choices.

If you practice intermittent fasting, be aware that long-term use (especially with very short eating windows like 8 hours) may increase your risk of heart disease and mortality, particularly if you have existing heart conditions or genetic risks. The benefits seen in short-term studies (less than 12 weeks) do not necessarily translate to long-term health. Focus on preserving muscle mass, eating nutrient-dense foods, and consider combining fasting with exercise or switching to a Mediterranean diet for better long-term cardiovascular outcomes.

Low-Carbohydrate High-Fat (LCHF) and Ketogenic diets do not significantly alter ALT levels in individuals with MASLD compared to control diets.

Current evidence from this meta-analysis does not support LCHF or Ketogenic diets as significantly effective for lowering liver enzymes (ALT) in people with MASLD compared to control diets. The wide variation in how 'low-carb' was defined across studies makes it difficult to draw firm conclusions, but it did not show the significant benefits seen with fasting or MedDiet.

Omega-3 fatty acid supplementation does not significantly alter ALT levels in individuals with MASLD.

Taking Omega-3 fatty acid supplements does not significantly lower liver enzymes (ALT) in people with MASLD compared to control groups. While Omega-3s are generally healthy, they should not be relied upon as a primary treatment for improving liver health biomarkers in this condition.

GLP-1 receptor agonist therapy improves tear production and tear film stability in patients with type 2 diabetes compared to non-GLP-1 RA therapies.

If you have Type 2 Diabetes and are considering or using GLP-1 RAs (like semaglutide or dulaglutide), this research suggests these medications might actually help keep your eyes moist and stable compared to other diabetes drugs. While this doesn't replace standard dry eye treatments, it is a potential benefit to discuss with your doctor, especially if you suffer from dry eye symptoms.

Endoscopic Bariatric Procedures (EBP), including intragastric balloon (IGB), aspiration therapy (AT), and primary obesity surgery endoluminal (POSE), are generally less effective than newer OMMs (semaglutide, tirzepatide) and have limited long-term data.

Endoscopic procedures (IGB, AT, POSE, ESG) offer moderate weight loss (3.8-12.8% TBWL) in the short term but are generally less effective than newer medications (semaglutide, tirzepatide) and lack long-term efficacy data. They may be considered for patients who are not candidates for surgery or high-dose medications, but they are not the most effective option for significant, sustained weight loss.

Network pharmacology analysis suggests that the synergistic mechanism of combined exercise and medication involves the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network.

This is a mechanistic hypothesis. It suggests that combining exercise and medication may work by reducing inflammation (IL1B-STAT3) and improving lipid metabolism (SIRT1/CD36).